Suntharalingam M, et al. - The authors aimed at determining the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treatment of esophageal carcinoma. They recognized no improvement in overall survival with the addition of cetuximab to concurrent chemoradiation. Results here suggested little benefit to current epidermal growth factor receptor-targeted agents in an unselected patient population and underscored the necessity for predictive biomarkers in the treatment of esophageal cancer.